Consun Pharmaceutical Group Limited (HKG: 1681)

Consun Pharmaceutical Group Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2,739	2,590	2,340	2,045	1,753	1,728
Revenue Growth (YoY)	11.08%	10.71%	14.43%	16.65%	1.42%	-6.28%
Cost of Revenue	706.2	668.44	576.74	517.32	431.16	466.85
Gross Profit	2,033	1,922	1,763	1,527	1,322	1,261
Selling, General & Admin	1,216	1,168	1,094	900	746	700.69
Other Operating Expenses	-61.55	-59.45	-14.47	-14.8	-3.82	-6.01
Operating Expenses	1,150	1,096	1,048	867.15	771.54	765.03
Operating Income	882.91	825.92	715.41	660.18	550.13	496.38
Interest Expense	-27.43	-21.26	-10.93	-12.91	-21.4	-23.39
Interest & Investment Income	79.98	68.92	52.41	39.25	27.89	16.75
Currency Exchange Gain (Loss)	-14.65	-9.03	-9.28	11.33	27.37	-23.96
Other Non Operating Income (Expenses)	-	-	-	-	-	-5.65
EBT Excluding Unusual Items	920.81	864.55	747.61	697.85	583.98	460.13
Impairment of Goodwill	-	-	-	-	-	-320.65
Gain (Loss) on Sale of Assets	-0.75	-0.85	-1.22	-1.99	-0.24	-0.33
Asset Writedown	-	-	-	-	-	-5.49
Pretax Income	920.06	863.7	746.39	695.86	583.74	133.66
Income Tax Expense	80.37	77.15	62.7	108.74	101.99	70.54
Earnings From Continuing Operations	839.68	786.55	683.7	587.12	481.74	63.12
Minority Interest in Earnings	-3.28	-2.02	-0.79	3.06	17.05	16.7
Net Income	836.41	784.53	682.91	590.17	498.79	79.82
Net Income to Common	836.41	784.53	682.91	590.17	498.79	79.82
Net Income Growth	13.94%	14.88%	15.71%	18.32%	524.89%	-82.85%
Shares Outstanding (Basic)	797	791	791	802	817	849
Shares Outstanding (Diluted)	806	799	792	805	817	854
Shares Change (YoY)	1.69%	0.91%	-1.58%	-1.54%	-4.35%	-2.68%
EPS (Basic)	1.05	0.99	0.86	0.74	0.61	0.09
EPS (Diluted)	1.04	0.98	0.86	0.73	0.61	0.09
EPS Growth	12.14%	13.95%	17.81%	19.67%	577.78%	-83.02%
Free Cash Flow	832.63	766.41	896.09	627.29	818.36	203.57
Free Cash Flow Per Share	1.03	0.96	1.13	0.78	1.00	0.24
Dividend Per Share	0.549	0.408	0.265	0.244	0.236	0.179
Dividend Growth	35.79%	53.93%	8.58%	3.66%	31.87%	1.79%
Gross Margin	74.22%	74.19%	75.35%	74.70%	75.40%	72.99%
Operating Margin	32.24%	31.89%	30.58%	32.29%	31.39%	28.72%
Profit Margin	30.54%	30.29%	29.19%	28.86%	28.46%	4.62%
Free Cash Flow Margin	30.40%	29.59%	38.30%	30.68%	46.69%	11.78%
EBITDA	955.46	897.51	785.89	728.71	618.79	566.36
EBITDA Margin	34.88%	34.65%	33.59%	35.64%	35.30%	32.77%
D&A For EBITDA	72.55	71.58	70.48	68.53	68.66	69.98
EBIT	882.91	825.92	715.41	660.18	550.13	496.38
EBIT Margin	32.23%	31.89%	30.58%	32.29%	31.39%	28.72%
Effective Tax Rate	8.74%	8.93%	8.40%	15.63%	17.47%	52.78%

Source: S&P Capital IQ. Standard template. Financial Sources.